David A. Siegel Lineage Cell Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 11,700 shares of LCTX stock, worth $22,230. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,700

Previous 14,500 19.31%

Holding current value

$22,230

Previous $13,000 53.85%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$0.87 - $1.79 $2,436 - $5,012	-2,800 Reduced 19.31%	11,700 $20,000
Q2 2025 Aug 14, 2025	SELL	$0.39 - $1.13 $81,456 - $236,016	-208,864 Reduced 93.51%	14,500 $13,000
Q1 2025 May 15, 2025	BUY	$0.45 - $0.72 $61,380 - $98,208	136,400 Added 156.85%	223,364 $100,000
Q4 2024 Feb 14, 2025	BUY	$0.5 - $0.95 $32,932 - $62,570	65,864 Added 312.15%	86,964 $43,000
Q3 2024 Nov 14, 2024	SELL	$0.8 - $1.12 $1,120 - $1,568	-1,400 Reduced 6.22%	21,100 $19,000

Q2 2024 Aug 14, 2024	SELL	$0.89 - $1.47 $8,811 - $14,553	-9,900 Reduced 30.56%	22,500 $22,000
Q1 2024 May 15, 2024	SELL	$0.86 - $1.48 $4,730 - $8,140	-5,500 Reduced 14.51%	32,400 $47,000
Q4 2023 Feb 14, 2024	SELL	$0.91 - $1.35 $1,092 - $1,620	-1,200 Reduced 3.07%	37,900 $41,000
Q3 2023 Nov 14, 2023	SELL	$1.16 - $1.53 $12,178 - $16,063	-10,499 Reduced 21.17%	39,100 $46,000
Q2 2023 Aug 14, 2023	SELL	$1.26 - $1.53 $22,050 - $26,775	-17,500 Reduced 26.08%	49,599 $69,000
Q1 2023 May 15, 2023	SELL	$1.2 - $1.53 $26,476 - $33,757	-22,064 Reduced 24.75%	67,099 $100,000
Q4 2022 Feb 14, 2023	SELL	$1.02 - $1.5 $133,518 - $196,350	-130,900 Reduced 59.48%	89,163 $104,000
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $48,593 - $76,115	-43,003 Reduced 16.35%	220,063 $249,000
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $395,024 - $567,847	-352,700 Reduced 57.28%	263,066 $416,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $574,266 - $1.18 Million	-474,600 Reduced 43.53%	615,766 $948,000
Q4 2021 Feb 14, 2022	SELL	$1.84 - $2.68 $40,480 - $58,960	-22,000 Reduced 1.98%	1,090,366 $2.67 Million
Q3 2021 Nov 15, 2021	SELL	$2.26 - $2.86 $1.61 Million - $2.04 Million	-712,200 Reduced 39.03%	1,112,366 $2.8 Million
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $413,819 - $572,100	190,700 Added 11.67%	1,824,566 $5.2 Million
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $1.99 Million - $3.48 Million	1,124,000 Added 220.45%	1,633,866 $3.84 Million
Q4 2020 Feb 16, 2021	BUY	$0.95 - $1.83 $163,590 - $315,126	172,200 Added 51.0%	509,866 $897,000
Q3 2020 Nov 16, 2020	BUY	$0.75 - $1.09 $34,425 - $50,031	45,900 Added 15.73%	337,666 $316,000
Q2 2020 Aug 14, 2020	BUY	$0.71 - $1.18 $41,322 - $68,676	58,200 Added 24.92%	291,766 $254,000
Q1 2020 May 15, 2020	SELL	$0.6 - $1.58 $7,680 - $20,224	-12,800 Reduced 5.2%	233,566 $193,000
Q4 2019 Feb 14, 2020	BUY	$0.54 - $1.01 $31,536 - $58,984	58,400 Added 31.07%	246,366 $219,000
Q3 2019 Nov 14, 2019	BUY	$0.85 - $1.24 $159,771 - $233,077	187,966 New	187,966 $184,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account